Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation

Area of Science:

• Genetics and Molecular Biology
• Pharmacology
• Medical Science

Background:

• Cystic fibrosis (CF) is a common, life-shortening autosomal recessive disease.
• The discovery of the CFTR gene in 1989 opened avenues for therapeutic targets.
• Current protein repair therapies for CFTR mutations have not yet succeeded in clinical trials.

Purpose of the Study:

• To explore small molecule discovery as a novel therapeutic strategy for CF.
• To investigate the potential of small organic compounds to restore mutant CFTR protein function.
• To review progress and outstanding questions in CFTR-targeted therapies.

Main Methods:

• Identification, evaluation, and optimization of small organic compounds.
• Classification of over 1300 identified CFTR mutations into five broad groups.
• In vitro testing of interventions to restore CFTR function for different mutation classes.

Main Results:

• Small molecule discovery represents a promising area for developing CF therapeutics.
• In vitro studies demonstrated the ability of interventions to restore some CFTR function across various mutation classes.
• Over 1300 CFTR mutations have been identified and categorized.

Conclusions:

• Small molecule-based protein repair therapy holds potential for treating cystic fibrosis.
• Further clinical trials are needed to validate the efficacy of CFTR repair strategies.
• Key questions regarding required CFTR correction levels, delivery methods, and combination therapies remain to be addressed.